Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non‐valvular atrial fibrillation and …
WL Baker, J Beyer‐Westendorf, TJ Bunz… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aims To assess the effectiveness and safety of rivaroxaban versus warfarin for the
prevention of major adverse cardiovascular events (MACE) and major adverse limb events …
prevention of major adverse cardiovascular events (MACE) and major adverse limb events …
Effectiveness and safety of rivaroxaban vs warfarin in people with non‐valvular atrial fibrillation and diabetes: an administrative claims database analysis
CI Coleman, TJ Bunz, D Eriksson… - Diabetic …, 2018 - Wiley Online Library
Aim To assess the effectiveness and safety of rivaroxaban vs warfarin in people with non‐
valvular atrial fibrillation and diabetes treated in routine practice. Methods Using US …
valvular atrial fibrillation and diabetes treated in routine practice. Methods Using US …
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
CI Coleman, OS Costa, CW Brescia, B Vardar… - Cardiovascular …, 2021 - Springer
Background Diabetes increases a patient's risk of developing atrial fibrillation by 49%.
Patients with nonvalvular atrial fibrillation are at a fivefold increased risk of stroke and die …
Patients with nonvalvular atrial fibrillation are at a fivefold increased risk of stroke and die …
[HTML][HTML] Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition …
S Bansilal, Z Bloomgarden, JL Halperin… - American Heart …, 2015 - Elsevier
Background The prevalence of both atrial fibrillation (AF) and diabetes mellitus (DM) are
rising, and these conditions often occur together. Also, DM is an independent risk factor for …
rising, and these conditions often occur together. Also, DM is an independent risk factor for …
[HTML][HTML] Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
MR Weir, YW Chen, J He, B Bookhart… - Journal of Diabetes and …, 2021 - Elsevier
Aims To compare clinical outcomes of rivaroxaban and warfarin in patients with nonvalvular
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …
The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a systematic review and meta-analysis
Y Hua, JY Sun, Y Su, Q Qu, HY Wang, W Sun… - American Journal of …, 2021 - Springer
Aims This meta-analysis was conducted to compare the efficacy and safety of rivaroxaban
with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus. Methods PubMed …
with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus. Methods PubMed …
[HTML][HTML] Comparison of the incidence of major bleeding with rivaroxaban use among nonvalvular atrial fibrillation patients with versus without diabetes mellitus
WF Peacock, S Tamayo, N Sicignano, KP Hopf… - The American Journal of …, 2017 - Elsevier
Diabetes mellitus (DM) is a common co-morbidity in those with nonvalvular atrial fibrillation
(NVAF). Most patients with DM and NVAF have a CHA 2 DS 2-VASc score of≥ 1 and should …
(NVAF). Most patients with DM and NVAF have a CHA 2 DS 2-VASc score of≥ 1 and should …
Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes
AV Hernandez, G Bradley, M Khan… - … Journal-Quality of …, 2020 - academic.oup.com
Aims Vascular calcification is common in diabetic patients. Warfarin has been associated
with renovascular calcification and worsening renal function; rivaroxaban may provide …
with renovascular calcification and worsening renal function; rivaroxaban may provide …
Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a subgroup analysis of the ROCKET AF trial
JL Halperin, Z Bloomgarden, A Hellkamp… - 2012 - Am Heart Assoc
Background: In patients with nonvalvular AF enrolled in ROCKET AF, rivaroxaban was
noninferior to warfarin for prevention of stroke and systemic embolism and caused less …
noninferior to warfarin for prevention of stroke and systemic embolism and caused less …
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease
CI Coleman, WL Baker, AK Meinecke… - European Heart …, 2020 - academic.oup.com
Aims There are scarce data evaluating the effectiveness and safety of rivaroxaban vs.
warfarin in non-valvular atrial fibrillation (NVAF) patients with concomitant coronary artery …
warfarin in non-valvular atrial fibrillation (NVAF) patients with concomitant coronary artery …
相关搜索
- atrial fibrillation safety of rivaroxaban
- atrial fibrillation warfarin in patients
- limb events warfarin for prevention
- warfarin for prevention safety of rivaroxaban
- limb events safety of rivaroxaban
- warfarin in patients effectiveness and safety
- fibrillation patients rivaroxaban use
- fibrillation patients major bleeding
- atrial fibrillation limb events
- rivaroxaban or warfarin vascular death
- warfarin in patients efficacy of rivaroxaban
- obesity and diabetes safety of rivaroxaban
- fibrillation patients vascular death
- fibrillation patients obesity and diabetes
- atrial fibrillation incident diabetes
- atrial fibrillation effectiveness and safety